AIP
BLPH

Ameritas Investment Partners’s Bellerophon Therapeutics, Inc. BLPH Stock Holding History

Ameritas Investment Partners’s Portfolio BLPH Stock Details BLPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-304
Closed -$2K – 3369
2021
Q1 		$2K Hold
304
– – ﹤0.01% 3085
2020
Q4 		$2K Hold
304
– – ﹤0.01% 3057
2020
Q3 		$3K Hold
304
– – ﹤0.01% 3057
2020
Q2 		$4K Buy
+304
New +$4.25K ﹤0.01% 3012

Other funds holding BLPH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Ameritas Investment Partners's BLPH Position: Q2 2021 in Review

Ameritas Investment Partners sold out of Bellerophon Therapeutics, Inc. (BLPH) in Q2 2021, closing a stake of 304 shares — an estimated $2K sold.

Ameritas Investment Partners first reported a position in BLPH in Q2 2020 and held it in 4 quarters. The position peaked at $4K in Q2 2020. 27 funds tracked by Wall St. Rank hold BLPH as of Q2 2021.

  • Ameritas Investment Partners reported no remaining Bellerophon Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
  • Ameritas Investment Partners sold 304 Bellerophon Therapeutics, Inc. shares in Q2 2021, an estimated $2K.
  • Ameritas Investment Partners first reported a position in Bellerophon Therapeutics, Inc. in Q2 2020 and held it in 4 quarters.
  • Ameritas Investment Partners's Bellerophon Therapeutics, Inc. position peaked at $4K in Q2 2020.
  • 27 funds tracked by Wall St. Rank held Bellerophon Therapeutics, Inc. as of Q2 2021.

Based on Ameritas Investment Partners's 13F filing for Q2 2021, filed 6 Aug 2021.